Everything below concerns Nicotinamide mononucleotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-17. Numbers and descriptions here follow the published literature rather than marketing material.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
=== Br === Roscoe Brady (1923–2016). American biochemist at the National Institute of Neurological Disorders and Stroke, who identified many enzyme defects responsible for metabolic diseases. Member Natl. Acad. Sci. USA. Herman Branson (1914–1995). American physicist and biochemist who participated at Caltech in the discovery of the α-helix Sydney Brenner (1927–2019). South African biochemist at Cambridge, and later Berkeley, known for work on the genetic code and more recently for establishing Caenorhabditis elegans as a model organism. Nobel prize in Physiology or Medicine (2002) Roger Brent (b. 1955). American molecular biologist at the University of Washington known for work on gene regulation and systems biology Kenneth Breslauer (b. 1947). American biochemist at Rutgers University (born in Sweden of German parents), who has studied DNA damage and repair, including why certain mutations escape repair and result in cancer. Bernard Brodie (1907–1989). American biochemist and pharmacologist at the National Heart Institute, regarded as the founder of modern pharmacology. He studied drug metabolism and the mechanisms of drug effects. Member Natl. Acad. Sci. USA. Adrian John Brown FRS (1852–1920). British expert on brewing and malting at the University of Birmingham. He was a pioneer of enzyme kinetics and proposed an explanation of enzyme saturation. Patrick O. Brown (b. 1954). American biochemist at Stanford.
=== Block === In most US cities, a city block is between 1⁄16 and 1⁄8 mi (100 and 200 m). In Manhattan, the measurement "block" usually refers to a north–south block, which is 1⁄20 mi (80 m). Sometimes people living in places (like Manhattan) with a regularly spaced street grid will speak of long blocks and short blocks. Within a typical large North American city, it is often only possible to travel along east–west and north–south streets, so travel distance between two points is often given in the number of blocks east–west plus the number north–south (known to mathematicians as the Manhattan distance).
== Synthesis == PFOA has two main synthesis routes, electrochemical fluorination (ECF) and telomerization. The ECF route sees octanoyl chloride (the acid chloride of octanoic acid) reacted with hydrofluoric acid. Multiple products are formed by ECF with the target acid fluoride F(CF2)7COF being produced as only 10–15% of the yield, while the main products are perfluorinated cyclic ether isomers, including FC-75. This acid fluoride is hydrolyzed to yield PFOA as a mixture of straight-chain (78%), terminally branched (13%), and internally branched (9%) molecules, because ECF induces rearrangements in the carbon tail of the acid chloride. ECF also results in production wastes. 3M synthesized ECF PFOA at their Cottage Grove, Minnesota facility from 1947 to 2002 and was the world's largest producer. ECF production continues on a smaller scale in Europe and Asia. PFOA is also synthesized by the telomerization represented below, where the telogen is the organoiodine compound and the taxogen is the tetrafluoroethylene. Each step is an addition reaction where the carbon-iodine bond of the telogen is added across the carbon-carbon double bond of the unsaturated taxogen, resulting in the formation of a new telogen.
In August 2025, Moore's chief of staff, Fagan Harris, announced that he would resign his post at the end of the year to become the next president of the Abell Foundation; he was succeeded by Lester Davis, a CareFirst BlueCross BlueShield executive who worked as an unpaid outside advisor to Moore's 2022 gubernatorial campaign. In October 2025, Roland Butler resigned as secretary of state police and was succeeded by state senator Michael A. Jackson. In November 2025, Paul Monteiro resigned as secretary of Maryland Department of Service and Civic Innovation and was succeeded by Jonny Dorsey, one of Moore's deputy chiefs of staff. In October 2025, Moore appointed Walter Simmons to serve as the secretary of the newly created Department of Social and Economic Mobility. Two of Moore's cabinet secretaries resigned in 2026. Maryland Secretary of Human Services Rafael López, who resigned on February 23, citing health reasons, and was succeeded by deputy secretary Gloria Brown Burnett, who will serve as acting secretary until April 1, when Stacy Rodgers will then take over as acting secretary. In March 2026, Rai announced that he would step down on March 27, and would be succeeded by deputy secretary Elena Quiroz-Livanis, who will serve as acting secretary until a search for a new, permanent secretary is completed.
Sources: en.wikipedia.org
Opioid prescriptions in the US increased from 76 million in 1991 to 207 million in 2013. In the 1990s, opioid prescribing increased significantly. Once used almost exclusively for the treatment of acute pain or pain due to cancer, opioids are now prescribed liberally for people experiencing chronic pain. This has been accompanied by rising rates of accidental addiction and accidental overdoses leading to death. According to the International Narcotics Control Board, the United States and Canada lead the per capita consumption of prescription opioids. The number of opioid prescriptions per capita in the United States and Canada is double the consumption in the European Union, Australia, and New Zealand. Certain populations have been affected by the opioid addiction crisis more than others, including First World communities and low-income populations. Public health specialists say that this may result from the unavailability or high cost of alternative methods for addressing chronic pain. Opioids have been described as a cost-effective treatment for chronic pain, but the impact of the opioid epidemic and deaths caused by opioid overdoses should be considered in assessing their cost-effectiveness. Data from 2017 suggest that in the U.S. about 3.4 percent of the U.S. population are prescribed opioids for daily pain management. Calls for opioid deprescribing have led to broad scale opioid tapering practices with little scientific evidence to support the safety or benefit for patients with chronic pain.
Concentrations of equilin that are very high relative to those of other estrogens are produced by typical clinical doses of CEEs. With a dosage of 1.25 mg oral CEEs, equilin levels of 1,082 to 2,465 pg/mL have been observed. The clinical significance of these levels of equilin is unknown. The active forms are metabolized primarily in the liver. There is some enterohepatic recirculation of CEEs. Following a single oral dose of 0.625 CEEs, the biological half-life of estrone was 26.7 hours, of baseline-adjusted estrone was 14.8 hours, and of equilin was 11.4 hours.
Transition options for transgender adolescents and youth are significantly limited compared to those for transgender adults. Prepubescent transgender youth can go through various social changes, such as presenting as their gender and asking to be called by a different name or different pronouns. Medical options for transition become available once the child begins to enter puberty. Under close supervision by a team of doctors, puberty blockers may be used to limit the effects of puberty. Discrimination has a significant effect on the mental health of young transgender people. The lack of family acceptance, rejection in schools and abuse from peers can be powerful stressors, leading to poor mental health and substance abuse. A study done on transgender youth in San Francisco found that higher rates of both transgender-based and racial bias are associated with increased rates of depression, post-traumatic stress disorder, and suicidal ideation. The Swiss National Advisory Commission on Biomedical Ethics (NCE) has suggested that research into treatments for gender-incongruent and gender-diverse young people should routinely consider the impact of social factors, including discrimination and social support, when analyzing their results. In a 2018 review, evidence suggested that hormonal treatments for transgender adolescents can achieve their intended physical effects.
== Management == Biomedical waste must be properly managed and disposed of to protect the environment, general public and workers, especially healthcare and sanitation workers who are at risk of exposure to biomedical waste as an occupational hazard. Steps in the management of biomedical waste include generation, accumulation, handling, storage, treatment, transport and disposal. The development and implementation of a national waste management policy can improve biomedical waste management in health facilities in a country.
Synthetic organic chemistry is an applied science as it borders engineering, the "design, analysis, and/or construction of works for practical purposes". Organic synthesis of a novel compound is a problem-solving task, where a synthesis is designed for a target molecule by selecting optimal reactions from optimal starting materials. Complex compounds can have tens of reaction steps that sequentially build the desired molecule. The synthesis proceeds by utilizing the reactivity of the functional groups in the molecule. For example, a carbonyl compound can be used as a nucleophile by converting it into an enolate, or as an electrophile; the combination of the two is called the aldol reaction. Designing practically useful syntheses always requires conducting the actual synthesis in the laboratory. The scientific practice of creating novel synthetic routes for complex molecules is called total synthesis. Strategies to design a synthesis include retrosynthesis, popularized by E.J. Corey, which starts with the target molecule and splices it to pieces according to known reactions. The pieces, or the proposed precursors, receive the same treatment, until available and ideally inexpensive starting materials are reached. Then, the retrosynthesis is written in the opposite direction to give the synthesis. A "synthetic tree" can be constructed because each compound and also each precursor has multiple syntheses.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.